VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China
Filed with HKEX · Stock code 13 ·
Watch HUTCHMED (China)'s latest callHUTCHMED (China) (HKEX:13) Q2 2026 Earnings Call · Replay · Jul 30Read the transcript of HUTCHMED (China) (HKEX:13) Q2 2026 Earnings Call6ix is reading this filing.
View original source (HKEXnews)HUTCHMED (China) Limited on 6ix
Story so far
- VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces Submission of US NDA for ORPATHYS plus TAGRISSO in MET Driven EGFR-Mutated Lung Cancer
- VOLUNTARY ANNOUNCEMENT - HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
- VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
Earlier from HUTCHMED (China)
- Monthly Return of Equity Issuer on Movements in Securities for the month ended September 30, 2026
- VOLUNTARY ANNOUNCEMENT - HUTCHMED Announces Submission of US NDA for ORPATHYS plus TAGRISSO in MET Driven EGFR-Mutated Lung Cancer
- VOLUNTARY ANNOUNCEMENT - HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors
- VOLUNTARY ANNOUNCEMENT - HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
- HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy
Follow HUTCHMED (China) into a list and get an email when it puts out news.
Follow HUTCHMED (China)